HK1160169A1 - Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna (dmd) mrna 45 - Google Patents

Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna (dmd) mrna 45

Info

Publication number
HK1160169A1
HK1160169A1 HK12100495.6A HK12100495A HK1160169A1 HK 1160169 A1 HK1160169 A1 HK 1160169A1 HK 12100495 A HK12100495 A HK 12100495A HK 1160169 A1 HK1160169 A1 HK 1160169A1
Authority
HK
Hong Kong
Prior art keywords
mrna
dmd
exon
methods
muscular dystrophy
Prior art date
Application number
HK12100495.6A
Other languages
English (en)
Chinese (zh)
Inventor
Josephus Johannes De Kimpe
Gerardus Johannes Platenburg
Judith Christina Theodora Van Deutekom
Annemieke Aartsma-Rus
Garrit-Jan Boudewijn Van Ommen
Original Assignee
Prosensa Technologies Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40873329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1160169(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/NL2008/050673 external-priority patent/WO2009054725A2/en
Application filed by Prosensa Technologies Bv filed Critical Prosensa Technologies Bv
Publication of HK1160169A1 publication Critical patent/HK1160169A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
HK12100495.6A 2008-10-27 2012-01-16 Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna (dmd) mrna 45 HK1160169A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2008/050673 WO2009054725A2 (en) 2007-10-26 2008-10-27 Means and methods for counteracting muscle disorders
PCT/NL2009/050006 WO2010050801A1 (en) 2008-10-27 2009-01-13 Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna

Publications (1)

Publication Number Publication Date
HK1160169A1 true HK1160169A1 (en) 2012-08-10

Family

ID=40873329

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12100495.6A HK1160169A1 (en) 2008-10-27 2012-01-16 Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna (dmd) mrna 45

Country Status (15)

Country Link
EP (4) EP2344637B2 (xx)
JP (2) JP5786109B2 (xx)
AU (1) AU2009310557B2 (xx)
CA (3) CA2741629C (xx)
CY (1) CY1116305T1 (xx)
DK (2) DK2344637T4 (xx)
ES (2) ES2562658T3 (xx)
HK (1) HK1160169A1 (xx)
HR (1) HRP20160078T1 (xx)
IL (2) IL212509A (xx)
NZ (1) NZ592498A (xx)
PL (1) PL2607484T3 (xx)
PT (2) PT2344637E (xx)
SI (1) SI2607484T1 (xx)
WO (2) WO2010050801A1 (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807816B2 (en) 2004-06-28 2010-10-05 University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
CN101896186A (zh) 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
KR20230025924A (ko) * 2008-10-24 2023-02-23 사렙타 쎄러퓨틱스 인코퍼레이티드 Dmd를 위한 다중 엑손 스키핑 조성물
EP2480659A2 (en) * 2009-09-24 2012-08-01 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
EP2499249B1 (en) 2009-11-12 2018-08-08 The University Of Western Australia Antisense molecules and methods for treating pathologies
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
CN103501793A (zh) * 2011-02-08 2014-01-08 夏洛特-梅克伦堡医院(商业用名:卡罗来纳保健系统) 反义寡核苷酸
CN110055243B (zh) 2011-12-28 2024-03-26 日本新药株式会社 反义核酸
CN104203289B (zh) * 2012-01-27 2020-11-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
CN104603271B (zh) * 2012-07-03 2019-07-19 马林生物科技有限公司 用于治疗肌肉萎缩症患者的寡核苷酸
JP6449231B2 (ja) 2013-03-14 2019-01-09 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するためのエキソンスキッピング組成物
EA201591792A1 (ru) 2013-03-15 2016-02-29 Сарепта Терапьютикс, Инк. Улучшенные композиции для лечения мышечной дистрофии
EP3041935A1 (en) * 2013-09-05 2016-07-13 Sage Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
JP6519842B2 (ja) * 2013-10-04 2019-05-29 国立大学法人神戸大学 福山型筋ジストロフィー治療用アンチセンス核酸
US9988629B2 (en) * 2014-03-12 2018-06-05 Nippon Shinyaku Co., Ltd. Antisense nucleic acids
AU2015272128B2 (en) 2014-06-10 2021-10-28 Erasmus University Medical Center Rotterdam Antisense oligonucleotides useful in treatment of Pompe disease
MY185390A (en) * 2015-09-15 2021-05-17 Nippon Shinyaku Co Ltd Antisense nucleic acids
TW201722439A (zh) 2015-10-09 2017-07-01 波濤生命科學有限公司 寡核苷酸組合物及其方法
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
CA3014776A1 (en) * 2016-03-02 2017-09-08 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
KR102522059B1 (ko) 2016-04-18 2023-04-14 사렙타 쎄러퓨틱스 인코퍼레이티드 안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
MA45290A (fr) * 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
AU2017290231A1 (en) 2016-06-30 2019-02-07 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
EP4252845A2 (en) * 2016-07-05 2023-10-04 BioMarin Technologies B.V. Pre-mrna splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
CN110636866A (zh) 2016-12-19 2019-12-31 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
HUE060065T2 (hu) 2016-12-19 2023-01-28 Sarepta Therapeutics Inc Exonátugró oligomerkonjugátumok izomdisztrófiára
BR112019012647A2 (pt) 2016-12-19 2019-11-19 Sarepta Therapeutics Inc conjugados de oligômero de salto de éxon para distrofia muscular
CN110381980A (zh) 2017-01-06 2019-10-25 艾维迪提生物科学有限责任公司 核酸-多肽组合物以及诱导外显子跳读的方法
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
US20210145852A1 (en) 2017-09-28 2021-05-20 Sarepta Therapeutics, Inc. Combination Therapies for Treating Muscular Dystrophy
US11110180B2 (en) 2017-10-04 2021-09-07 Avidity Biosciences Inc. Nucleic acid-polypeptide compositions and uses thereof
SG11202005022YA (en) 2017-12-06 2020-06-29 Avidity Biosciences Inc Compositions and methods of treating muscle atrophy and myotonic dystrophy
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
WO2019241385A2 (en) * 2018-06-13 2019-12-19 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystropy
CA3108289A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2021532831A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020118246A1 (en) * 2018-12-06 2020-06-11 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
EP3980436A4 (en) 2019-06-06 2023-12-20 Avidity Biosciences, Inc. NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
KR20220118459A (ko) * 2019-12-19 2022-08-25 니뽄 신야쿠 가부시키가이샤 엑손 스키핑을 가능하게 하는 안티센스 핵산
BR112022012622A2 (pt) 2019-12-26 2022-09-06 Nippon Shinyaku Co Ltd Ácido nucleico antissenso que induz o salto do éxon 50
WO2021172498A1 (ja) 2020-02-28 2021-09-02 日本新薬株式会社 エクソン５１のスキッピングを誘導するアンチセンス核酸
CN115666589A (zh) 2020-03-19 2023-01-31 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511362A (ja) 1999-10-04 2003-03-25 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー 新規カルバメートおよび尿素類
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US6727355B2 (en) * 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
WO2004083432A1 (en) * 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US7807816B2 (en) * 2004-06-28 2010-10-05 University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
CA2605512A1 (en) * 2005-04-22 2006-10-26 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure.
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
CN101896186A (zh) 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
KR20230025924A (ko) * 2008-10-24 2023-02-23 사렙타 쎄러퓨틱스 인코퍼레이티드 Dmd를 위한 다중 엑손 스키핑 조성물
US9607308B2 (en) 2011-06-29 2017-03-28 American Express Travel Related Services Company, Inc. Spend based digital ad targeting and measurement

Also Published As

Publication number Publication date
AU2009310557A8 (en) 2011-09-29
ES2562658T3 (es) 2016-03-07
JP2012506697A (ja) 2012-03-22
AU2009310557B2 (en) 2014-09-11
EP3400948B1 (en) 2022-11-02
CY1116305T1 (el) 2017-02-08
EP2344637A1 (en) 2011-07-20
SI2607484T1 (sl) 2016-11-30
EP2607484A1 (en) 2013-06-26
WO2010050802A3 (en) 2010-08-12
DK2344637T4 (en) 2018-04-23
IL212508A0 (en) 2011-06-30
IL212509A0 (en) 2011-06-30
CA2741629C (en) 2022-07-05
EP2349287B1 (en) 2018-08-15
EP2344637B2 (en) 2018-02-28
WO2010050801A1 (en) 2010-05-06
AU2009310557A1 (en) 2010-05-06
JP5905260B2 (ja) 2016-04-20
ES2532634T3 (es) 2015-03-30
AU2009310558A8 (en) 2015-01-22
AU2009310558B2 (en) 2014-09-04
DK2344637T3 (en) 2015-02-02
DK2607484T3 (en) 2016-03-07
HRP20160078T1 (hr) 2016-04-08
CA2741793C (en) 2018-10-30
EP2607484B1 (en) 2016-01-06
NZ592498A (en) 2012-05-25
ES2532634T5 (es) 2018-04-30
IL212509A (en) 2016-04-21
EP3400948A1 (en) 2018-11-14
AU2009310558A1 (en) 2010-05-06
IL212508A (en) 2013-11-28
EP2344637B1 (en) 2014-12-24
CA3017539A1 (en) 2010-05-06
CA2741793A1 (en) 2010-05-06
WO2010050802A2 (en) 2010-05-06
PT2607484E (pt) 2016-03-09
EP2349287A2 (en) 2011-08-03
PL2607484T3 (pl) 2016-06-30
JP5786109B2 (ja) 2015-09-30
JP2012506698A (ja) 2012-03-22
CA2741629A1 (en) 2010-05-06
PT2344637E (pt) 2015-03-23

Similar Documents

Publication Publication Date Title
HK1160169A1 (en) Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna (dmd) mrna 45
HK1185098A1 (zh) 高效跳過裘馨氏肌肉營養不良症前體 外顯子 的方法和工具
IL282772B1 (en) A method for efficient exon skipping (44) in Duchenne muscular dystrophy and related measures
IL278833A (en) Antisense compounds for inducing axon termination and preparations containing them for the treatment of muscular dystrophy
EP2370721A4 (en) DEVICE AND METHOD FOR SUPPORTING AN EXTENDED ELEMENT
EP2296805A4 (en) PROCESS AND APPARATUS FOR THE MANUFACTURE OF TITANIUM ALUMINUM ALLOYS
ZA201100651B (en) Method for dispersing and separating nanotubes
GB2439464B (en) DC Offset removal apparatus and DC offset removal method
EP2373585A4 (en) METHOD AND APPARATUS FOR REMOVING GRAVILLONS FROM WASTEWATER
EP2350811A4 (en) METHOD AND APPARATUS FOR MODULE REDUCTION
EP2190986A4 (en) HYBRIDIZATION METHOD AND APPARATUS
EP2340315A4 (en) COMPOSITIONS AND METHODS FOR DETECTION OF JAK2 NUCLEIC ACID MUTATIONS
IL209324A0 (en) Aliskiren monofumarate and processes for preparation thereof
GB0911649D0 (en) Apparatus and method for sharing and reuse of structured knowledge artifacts
EP2495040A4 (en) AGITATOR DEVICE AND STIRRER HOOKS FOR THE SAME
GB0807303D0 (en) Method and apparatus for installing an advertising sign
EP2596597A4 (en) METHOD AND DEVICE FOR ADMINISTERING CONSUMPTION RIGHTS FOR MULTIMEDIA SERVICES
TWI368845B (en) Multimedia palying method and apparatus thereof
GB0918106D0 (en) Support apparatus and method
TWI371971B (en) De-interlacing method and apparatus
TWI347126B (en) Dynamic de-interlacing method and apparatus
GB0802982D0 (en) Method and apparatus for installing an advertising sign

Legal Events

Date Code Title Description
AM43 Amendment of standard patent following opposition or revocation proceedings in the designated patent office (acc. sect 43 patent ordinance)